Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IMMP, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Eftilagimod Alpha (IMP321) | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 · NCT06726265 | Active not recruiting |
| HLA-A2 peptides | Melanoma | Phase 1/2 · NCT00365937 | Terminated |
| Dose dense Adriamycin-cyclophosphamide (AC) i.v | Breast Cancer | Phase 2 · NCT07102940 | Not yet recruiting |
| Docetaxel-cyclophosphamide (TC) intravenous… | Breast Cancer | Phase 2 · NCT07102940 | Not yet recruiting |
| IMP761 | Healthy | Phase 1 · NCT06637865 | Completed |
| hepatitis B antigen alone (without alum) | Healthy | Phase 1 · NCT00354861 | Completed |
| Hepatitis B Vaccine | Healthy | Phase 1 · NCT00354861 | Completed |
Also used in these trials (approved or third-party drugs, not IMMP's own candidates): Paclitaxel, Carboplatin, Pemetrexed Disodium, Pembrolizumab, Montanide ISA51, Immunological peptides and immunological adjuvants, Avelumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IMMP holds $68.9M in cash and short-term investments and burns about $13.9M/quarter from operations, an estimated runway of 14.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 13 · Low
Based on our current cash flow forecasts, we anticipate that our available cash resources will be sufficient to support operations well into the first half of calendar year 2028.20-F, Oct 2026
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMMP files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Pete A. Meyers Director |
Insider | 4,052,173 | 0.27% | 2026-03-18 |
| Christian Mueller Chief Development Officer |
Insider | 3,774,048 | 0.26% | 2026-03-18 |
| Deanne Diem Miller Chief Operating Officer |
Insider | 2,867,305 | 0.19% | 2026-03-18 |
| Russell J Howard Director |
Insider | 1,717,977 | 0.12% | 2026-03-18 |
| Elisabeth Amanda Boyce Director |
Insider | 423,288 | 0.03% | 2026-03-18 |
| Frederic Joseph Daniel Triebel Director |
Insider | 170,610 | 0.01% | 2026-03-18 |
| Stephan Karel Gerard Winckels Chief Medical Officer |
Insider | 92,935 | 0.01% | 2026-03-18 |
| Marc Voigt Chief Executive Officer, Chief Financial |
Insider | 85,700 | 0.01% | 2026-03-18 |
Share count 1,473,721,306 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMMP and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →